BRIEF published on 06/16/2026 at 21:21, 7 hours 2 minutes ago Medincell: Key Results and Initiatives for 2025-2026 Innovation Treasury R&D Royalties Medincell
BRIEF published on 05/21/2026 at 19:29, 26 days 8 hours ago EMA Accepts Teva's Application for Long-Acting Schizophrenia Treatment Schizophrenia Treatment Teva Pharmaceuticals EMA Approval Olanzapine Injectable Long-acting Formulation
PRESS RELEASE published on 05/21/2026 at 19:24, 26 days 8 hours ago Inside Information / Other news releases European Medicines Agency accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable to treat schizophrenia in adults. Teva and Medincell announce EMA acceptance for innovative treatment option Schizophrenia Medincell Olanzapine Teva EMA
BRIEF published on 04/29/2026 at 13:44, 1 month 17 days ago Impressive sales growth for UZEDY® in Q1 2026 Schizophrenia Medincell Teva Pharmaceuticals UZEDY® Q1 2026 Sales
BRIEF published on 04/29/2026 at 13:44, 1 month 17 days ago UZEDY® Q1 2026 Sales Surge by 62% FDA Approvals Olanzapine LAI UZEDY® Sales Teva Partnership Medincell Growth
PRESS RELEASE published on 04/29/2026 at 13:39, 1 month 17 days ago Inside Information / Other news releases Medincell's partner Teva Pharmaceuticals reports UZEDY Q1 2026 net sales of $63M, a 62% increase year-on-year. Olanzapine LAI NDA accepted by FDA. Medincell focuses on long-acting injectable treatments across various therapeutic areas Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY Long-acting Injectable
BRIEF published on 04/20/2026 at 11:18, 1 month 26 days ago BNP Paribas Développement crosses a threshold at MEDICELL Euronext Paris Voting Rights BNP Paribas Threshold Crossing MEDICELL
BRIEF published on 04/02/2026 at 19:05, 2 months 14 days ago Medincell: Update on capital and voting rights Share Capital Voting Rights Shares Euronext AMF
BRIEF published on 02/20/2026 at 21:42, 3 months 24 days ago Teva's Olanzapine Injectable Suspension Gains FDA Nod Schizophrenia Olanzapine Teva Pharmaceuticals FDA Acceptance Long-acting Injectable
PRESS RELEASE published on 02/20/2026 at 21:37, 3 months 24 days ago Inside Information / Other news releases FDA accepts Teva's NDA for once-monthly olanzapine for schizophrenia treatment, addressing treatment gap. Teva and Medincell collaborate for innovative solution FDA Schizophrenia Medincell Olanzapine Teva
Published on 06/17/2026 at 00:35, 3 hours 48 minutes ago INEO Tech Corp. Announces Closing of Private Placement and Debt Settlement
Published on 06/17/2026 at 00:28, 3 hours 55 minutes ago Apex Critical Metals Announces Filing of Technical Report on the Rift Rare Earth Project
Published on 06/17/2026 at 00:10, 4 hours 13 minutes ago Panther Minerals Announces Brokered Private Placement of up to $3,000,000
Published on 06/17/2026 at 00:00, 4 hours 23 minutes ago Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
Published on 06/16/2026 at 23:10, 5 hours 13 minutes ago Crestone Air Partners, an Air T Business, Completes Acquisition of Arena Aviation Capital, Surpassing $3.6 Billion in Assets Under Management
Published on 06/17/2026 at 04:15, 8 minutes ago Frost & Sullivan White Paper Names Phancy Rise vGPU a Tier 1 Leading Platform
Published on 06/16/2026 at 19:05, 9 hours 18 minutes ago AT&S announces the Reference Share Price and the Conversion Price of the new deeply subordinated perpetual convertible bond with an early redemption option for the Company
Published on 06/16/2026 at 19:00, 9 hours 23 minutes ago R. STAHL Shareholders approve nearly all agenda items at the Annual General Meeting – Executive Board confirms annual forecast
Published on 06/16/2026 at 18:15, 10 hours 8 minutes ago SUCCESSFUL PRICING OF €900,000,000 SENIOR NOTES DUE 2033 BY BIRKENSTOCK GROUP B.V. & CO. KG AND NOTICE OF REDEMPTION OF 5.25% SENIOR NOTES DUE 2029 ISSUED BY BIRKENSTOCK FINANCING S.À R.L.
Published on 06/16/2026 at 11:44, 16 hours 38 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 5 hours ago BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 1 day 9 hours ago Reporting on share buyback transactions carried out between June 8 and June 11, 2026
Published on 06/15/2026 at 18:32, 1 day 9 hours ago Edenred strengthens its electric charging offering with the acquisition of The Mobility House Solutions
Published on 06/15/2026 at 18:30, 1 day 9 hours ago Increase in the resources allocated to the liquidity contract with ODDO BHF
